

Second Announcement and Call for Posters




Image created by Louise Birch

29th Symposium on Medicinal Chemistry in Eastern England

Thursday 26th April 2018

**Fielder Centre,
Hatfield, Hertfordshire, UK**



ROYAL SOCIETY
OF CHEMISTRY

BIOLOGICAL AND
MEDICINAL
CHEMISTRY
SECTOR

Organised by RSC-BMCS (Royal Society of Chemistry - Biological and Medicinal Chemistry Sector)

Synopsis

The Symposium on Medicinal Chemistry in Eastern England, known colloquially as the "Hatfield MedChem" meeting, is a highly successful, long-standing, one-day meeting which runs annually. The scientific program will comprise presentations showcasing medicinal chemistry case studies from tools to candidates, across a range of modalities, therapeutic areas and target classes, as well as covering more general topics from the forefront of drug discovery of relevance to medicinal chemists. The meeting aims to be informal and interactive and the event will offer excellent scientific and networking opportunities for all those working in medicinal chemistry and drug discovery.

Call for Posters

Abstract submissions are invited for poster presentation. Please [download](#) an abstract template from the event website and return it to the secretariat, by 23rd

Programme


- 09.00 Registration, refreshments and exhibition
09.30 Welcome and introduction
09.35 *Discovery of Padsevonil for the treatment of drug-resistant epilepsy* - Laurent Provins, UCB, Belgium
10.10 *Development of potent and selective ATM inhibitors for proof of concept studies in Huntington's disease* - Perla Breccia, Charles River Discovery, UK
10.45 *Discovery and characterisation of novel indoleamine 2,3-dioxygenase inhibitors* - Dean Boyall, Vertex Pharmaceuticals, UK
11.05 Refreshments and exhibition
11.35 *The development of hypoxia activated pro-drugs of the clinically approved KDAC inhibitor Panobinostat* - Stuart Conway, University of Oxford, UK
12.10 *A case study from DNA-encoded library screening* - Tom Miller, Shire, UK
12.45 Lunch and exhibition
13:50 Capps Green Zomaya Award presentation lecture
Discovery of GDC-0853: a highly potent, selective, and non-covalent Btk inhibitor
James Crawford, Genentech, USA
14.30 *From pan-kinase promiscuity to selective protein degradation using PROTACs* - Christopher Tinworth, GlaxoSmithKline, UK
14.50 *Scaling de novo design, from single target to disease portfolio* - Willem van Hoorn, ExScientia, UK
15.10 Refreshments and exhibition
15.40 Presentation title and speaker to be confirmed
16.00 *Non-cleavable pyrrolobenzodiazepine antibody-drug conjugates* - Stephen J Gregson, Spirogen, UK
16.20 *ASTX660, the first fragment-derived IAP antagonist in the clinic* - Ben Cons, Astex Pharmaceuticals, UK
16.55 Concluding remarks and close (at 17.00)

Registration

Registration is open - see [website](#) for details.

Secretariat Contact

Maggi Churchouse Events
Telephone: +44 (0)1359 221004
maggi@maggichurchoousevents.co.uk



Sponsors

Sponsors are encouraged to support this popular event.

Organising Committee

Seb Campos, GlaxoSmithKline
Adrian Hall, UCB
Nicole Hamblin, Charles River (chair)

Website: www.maggichurchoousevents.co.uk/BMCS (also www.rsc.org/bmcs)